A recent New York Times article reported that dozens of spine surgery patients at NewYork-Presbyterian/Weill Cornell Medical Center were treated with a product that was not approved for use in such procedures. Burst Biologics, Inc., the manufacturer of BioBurst, a stem cell treatment derived from umbilical cord blood, was issued a warning letter by the U.S. Food and Drug Administration (FDA) last year, citing possible contamination problems and insufficient screening of donors, making the…
By: Napoli Shkolnik
By: Napoli Shkolnik
